ReviewExpert review of vaccines2019
Logistical challenges and assumptions for modeling the failure of global cessation of oral poliovirus vaccine (OPV).
Review in Expert review of vaccines, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Quantifying the benefits of improved operations for polio outbreak response: A model-based analysis.Vaccine · 2026Article
- Article
- Increasing Population Immunity Prior to Globally-Coordinated Cessation of Bivalent Oral Poliovirus Vaccine (bOPV).Pathogens (Basel, Switzerland) · 2024Article
- The roles of CD4Molecular therapy. Nucleic acids · 2024Article
- Coordinated global cessation of oral poliovirus vaccine use: Options and potential consequences.Risk analysis : an official publication of the Society for Risk Analysis · 2024Review
- The impact of disruptions caused by the COVID-19 pandemic on global polio eradication.Vaccine · 2023Article
- Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response.Vaccine · 2023Article
- Looking back at prospective modeling of outbreak response strategies for managing global type 2 oral poliovirus vaccine (OPV2) cessation.Frontiers in public health · 2023Review
- Complexity of options related to restarting oral poliovirus vaccine (OPV) in national immunization programs after OPV cessation.Gates open research · 2023Article
- Updated Characterization of Outbreak Response Strategies for 2019-2029: Impacts of Using a Novel Type 2 Oral Poliovirus Vaccine Strain.Risk analysis : an official publication of the Society for Risk Analysis · 2021Article
- Global Transmission of Live Polioviruses: Updated Dynamic Modeling of the Polio Endgame.Risk analysis : an official publication of the Society for Risk Analysis · 2021Article
- Insights From Modeling Preventive Supplemental Immunization Activities as a Strategy to Eliminate Wild Poliovirus Transmission in Pakistan and Afghanistan.Risk analysis : an official publication of the Society for Risk Analysis · 2021Article
- Reflections on Modeling Poliovirus Transmission and the Polio Eradication Endgame.Risk analysis : an official publication of the Society for Risk Analysis · 2021Review
- Modeling Poliovirus Transmission in Borno and Yobe, Northeast Nigeria.Risk analysis : an official publication of the Society for Risk Analysis · 2021Article
- Updated Characterization of Post-OPV Cessation Risks: Lessons from 2019 Serotype 2 Outbreaks and Implications for the Probability of OPV Restart.Risk analysis : an official publication of the Society for Risk Analysis · 2021Review
- Potential Future Use, Costs, and Value of Poliovirus Vaccines.Risk analysis : an official publication of the Society for Risk Analysis · 2021Article
- Expected Implications of Globally Coordinated Cessation of Serotype 3 Oral Poliovirus Vaccine (OPV) Before Serotype 1 OPV.Risk analysis : an official publication of the Society for Risk Analysis · 2021Article
- Modeling and Managing Poliovirus Risks: We are Where we are….Risk analysis : an official publication of the Society for Risk Analysis · 2021Article
- Review of poliovirus modeling performed from 2000 to 2019 to support global polio eradication.Expert review of vaccines · 2020Review
- Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence.Cell host & microbe · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.